Who are BIIB091's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): KI1106 4g, QD, Treatment Choice (TC), HP-802-247, TAK-667, SCTB14, mini CYVE, without 3 maintenance courses.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/biib091.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

BIIB091 — Competitive Intelligence Brief

BIIB091 (BIIB091) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD47-targeting monoclonal antibody. Area: Oncology.

phase 2 CD47-targeting monoclonal antibody CD47 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BIIB091 (BIIB091) — Biogen. BIIB091 is a monoclonal antibody targeting CD47.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BIIB091 TARGET	BIIB091	Biogen	phase 2	CD47-targeting monoclonal antibody	CD47
KI1106 4g, QD	KI1106 4g, QD	Kuhnil Pharmaceutical Co., Ltd.	phase 3	CD47/SIRPα inhibitor	CD47/SIRPα axis
Treatment Choice (TC)	Treatment Choice (TC)	Astex Pharmaceuticals, Inc.	phase 3	SIRPα inhibitor	CD47
HP-802-247	HP-802-247	Healthpoint	phase 3	CD47 antibody	CD47
TAK-667	TAK-667	Takeda	phase 3	CD47 antibody	CD47
SCTB14	SCTB14	Sinocelltech Ltd.	phase 3	CD47/SIRPα axis inhibitor	CD47/SIRPα axis
mini CYVE, without 3 maintenance courses	mini CYVE, without 3 maintenance courses	Gustave Roussy, Cancer Campus, Grand Paris	phase 3	CD47/SIRPα inhibitor	CD47

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD47-targeting monoclonal antibody class)

Biogen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BIIB091 — Competitive Intelligence Brief. https://druglandscape.com/ci/biib091. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab